The company has completed successful pre-clinical studies with THBA to demonstrate efficacy and a clean safety profile, and will run clinical trials for both humans and pets in 2017. The first nutraceutical product could be used either on its own or in co-administration with current anti-diabetic therapies. The company was founded in 2013 financed mainly by private high net worth individuals.
As a spin-off company from the Federal Institute of Technology/ETH Zürich, we combine strong expertise in adipose tissue biology, diabetes and obesity with the top-notch synthetic chemistry of natural products and small molecules. Close interactions with academic collaboration partners, such as the ETH, will fuel our pipeline with innovative new approaches and molecules to tackle the epidemic of prediabetes, type 2 diabetes and obesity.